178 related articles for article (PubMed ID: 19552831)
1. Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
Rozzini L; Chilovi BV; Conti M; Bertoletti E; Zanetti M; Trabucchi M; Padovani A
Int Psychogeriatr; 2010 Feb; 22(1):114-9. PubMed ID: 19552831
[TBL] [Abstract][Full Text] [Related]
2. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
Knorr UB
Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic mechanism of antidepressant action in depressed patients.
Willner P; Hale AS; Argyropoulos S
J Affect Disord; 2005 May; 86(1):37-45. PubMed ID: 15820269
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
5. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Strawn JR; Mills JA; Croarkin PE
J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
[No Abstract] [Full Text] [Related]
6. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
Hieronymus F; Lisinski A; Nilsson S; Eriksson E
Lancet Psychiatry; 2019 Sep; 6(9):745-752. PubMed ID: 31303567
[TBL] [Abstract][Full Text] [Related]
7. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
Mallinckrodt CH; Prakash A; Houston JP; Swindle R; Detke MJ; Fava M
Neuropsychobiology; 2007; 56(2-3):73-85. PubMed ID: 18037817
[TBL] [Abstract][Full Text] [Related]
8. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
9. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.
Mowla A; Mosavinasab M; Haghshenas H; Borhani Haghighi A
J Clin Psychopharmacol; 2007 Oct; 27(5):484-7. PubMed ID: 17873681
[TBL] [Abstract][Full Text] [Related]
10. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Shih YC; Bekele NB; Xu Y
Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
[TBL] [Abstract][Full Text] [Related]
11. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
[TBL] [Abstract][Full Text] [Related]
12. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
13. Depression and Alzheimer's disease: symptom or comorbidity?
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
Am J Alzheimers Dis Other Demen; 2002; 17(6):338-44. PubMed ID: 12501480
[TBL] [Abstract][Full Text] [Related]
14. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.
Dell'Agnello G; Ceravolo R; Nuti A; Bellini G; Piccinni A; D'Avino C; Dell'Osso L; Bonuccelli U
Clin Neuropharmacol; 2001; 24(4):221-7. PubMed ID: 11479393
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Nemeroff CB; Entsuah R; Benattia I; Demitrack M; Sloan DM; Thase ME
Biol Psychiatry; 2008 Feb; 63(4):424-34. PubMed ID: 17888885
[TBL] [Abstract][Full Text] [Related]
16. Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants.
Kampf-Sherf O; Zlotogorski Z; Gilboa A; Speedie L; Lereya J; Rosca P; Shavit Y
J Affect Disord; 2004 Nov; 82(3):453-9. PubMed ID: 15555698
[TBL] [Abstract][Full Text] [Related]
17. A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
Lucchi E; Minicuci N; Magnifico F; Mondini S; Calza A; Avanzi S; Villani D; Bellelli G; Trabucchi M
Arch Gerontol Geriatr Suppl; 2004; (9):253-63. PubMed ID: 15207422
[TBL] [Abstract][Full Text] [Related]
18. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
[TBL] [Abstract][Full Text] [Related]
19. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
[TBL] [Abstract][Full Text] [Related]
20. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
